drugset / Trial / NCT05863442
Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
This study is designed as a randomized, double-blind, parallel-group study to evaluate the PK, safety, tolerability, immunogenicity, and PD of TUR03 compared to Soliris, when administered as a single IV infusion in healthy adult male participants.
Timeline
- Start
- 2023-04-10
- Primary completion
- 2024-07-23
- Completion
- 2024-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eculizumab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | TUR03 | Unknown | 300 mg | Intravenous |
Indications
No indication recorded.